Sugi Predict

Sugi Predict / Compounds / SCHEMBL6877487

SCHEMBL6877487

SCHEMBL6877487

Cc1cc2c(cc1-c1ccccc1/C=C/C(=O)Cl)C(C)(C)CCC2(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 17/20 0.50
▸ RARG P13631 9/20 0.45
▸ RARB P10826 7/20 0.45
▸ RXRG P48443 11/20 0.43
▸ RXRB P28702 10/20 0.43
▸ RARA P10276 5/20 0.43
▸ MEN1 O00255 1/20 0.37
▸ CYP26A1 O43174 1/20 0.37
▸ ABCB11 O95342 1/20 0.37
▸ ESR1 P03372 1/20 0.37
▸ PGR P06401 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ DRD1 P21728 1/20 0.37
▸ TBXA2R P21731 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ ADRA1A P35348 1/20 0.37
▸ OPRM1 P35372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8189841 0.83 RXRA (0.62) RXRARARGRARBRXRGRXRB
SCHEMBL6874278 0.83 RXRA (0.47) RXRARARGRARBRXRGRXRB
SCHEMBL8189844 0.83 RXRA (0.62) RXRARARGRARBRXRGRXRB
SCHEMBL6870432 0.82 RXRA (0.46) RXRARARGRARBRXRGRXRB
SCHEMBL7878427 0.81 RARG (0.57) RXRARARGRARBRXRGRXRB
SCHEMBL7878425 0.81 RARG (0.57) RXRARARGRARBRXRGRXRB
SCHEMBL6870421 0.80 MAOA (0.50) RXRAMEN1RECQLKMT2A
SCHEMBL7466373 0.80 RXRA (0.46) RXRARARGRARBRXRGRXRB
SCHEMBL9049173 0.80 RXRA (0.42) RXRARARGRARBRXRGRXRB
SCHEMBL9049181 0.80 RXRA (0.42) RXRARARGRARBRXRGRXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825360-B1 Bicyclic aromatic compounds GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-11-30 — — US disclosed
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics BERNARDON JEAN-MICHEL 2003-07-17 — — US disclosed
US-20030060491-A1 Bicyclic aromatic compounds BERNARDON JEAN-MICHEL (FR) 2003-03-27 — — US disclosed
US-6515021-B1 Bicyclic aromatic compounds CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2003-02-04 — — US disclosed
US-6147255-A TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2000-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060491-A1 Bicyclic aromatic compounds MITF, TYR, PAH RXRA 196/4885RARG 474/4885RARB 529/4885
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics MITF, TYR, PAH RXRA 55/4885RARG 69/4885RARB 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.